Navigation Links
Prostate cancer stem cells are a moving target, UCLA researchers say
Date:12/4/2013

ction of hormones such as testosterone that make the cancer more aggressive. The tumor stem cells that remain after the anti-androgen treatment look different from the basal and luminal cells. This means that for treatments that target specific cell types, researchers need to identify the different cell types that evolve as the disease and its treatment progress.

With the knowledge that prostate cancer stem cells can change their physical appearance, or phenotype, from one type of cell to another, the UCLA researchers are now seeking to understand whether certain elements of the stem cells remain consistent even as they evolve from one cell type to another. This knowledge could help scientists develop drugs that target the evolving cancer stem cells by aiming for the elements that remain unchanged.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
4. Study examines adverse effects among different radiation therapies for prostate cancer
5. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
6. Warren Buffett Has Early Stage Prostate Cancer
7. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
8. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
11. Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at the ... Cancer Institute have received an $8 million grant from ... of photodynamic light therapy (PDT) in patients with malignant ... most often manifests itself in the lining of the ... asbestos. The grant will fund a clinical trial and ...
(Date:7/9/2014)... metabolism of stromal support cells and immune cells ... types in the development of diseases could open ... That was the conclusion of a review article by ... journal Nature . , Prof. Peter Carmeliet: "Consider ... metabolism of cancer cells has been examined in minute ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... Cup highlights, Brian Williams refreshing old school rap classics, ... railings. A University of Colorado Cancer Center study published ... YouTube also allows researchers, journals, and health advocates to ... cancer and prevention. , "No matter what field you,re ... communicate around the world," says Chante Karimkhani, MD candidate ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... , MINNEAPOLIS, June 9 Nonin Medical, Inc., ... history today by announcing the world,s first Bluetooth(R)-enabled ... now certified as compliant to the Continua(TM) Version ... Device Profile (HDP) and ISO/IEEE 11073 data protocol, ...
... from the Virginia Bioinformatics Institute (VBI) at Virginia Tech ... that allows them to profile in detail complex cellular ... to look at how the levels of proteins change ... hormones or cancer drugs like tamoxifen. VBI Assistant ...
... June 9 /PRNewswire-FirstCall/ -- Apria Healthcare Group ... ) (NYSE: PER ) today announced an ... to Apria Healthcare a range of healthcare information technology solutions, ... as well as consulting services. The term of the ...
... Resort Sponsors Scottish-Themed Charity Event , , OAK BROOK, Ill., June 9 ... night at the Oak Brook Hills Marriott Resort in Illinois. From 4:30 p.m. ... will be hosting the Oak Brook Hills Golf Classic to benefit the ... will feature: , , , ...
... you are getting full when eating a large meal? New ... may partially explain why severely obese individuals may not feel ... of food they consume during a meal. Researchers led ... and Diabetes Research Center focused on habituation, or the idea ...
... researchers determine that race has no bearing on life expectancy ... Older adults with mild cognitive impairment or Alzheimer,s disease have ... risk of death is no greater for whites or blacks, ... at Rush University Medical Center in Chicago, contradicts earlier information ...
Cached Medicine News:Health News:Nonin Medical, Inc. Announces the First Bluetooth(R) Continua(TM) Certified Product 2Health News:VBI researchers develop new method for breast cancer biomarker discovery 2Health News:Apria Healthcare Awards Technology Solutions Contract to Perot Systems 2Health News:Apria Healthcare Awards Technology Solutions Contract to Perot Systems 3Health News:Oak Brook Hills Golf Classic to Benefit the Children's Miracle Network 2Health News:Physiological response may explain why some severely obese patients overeat 2Health News:Alzheimer's and Even Mild Dementia Hasten Death 2
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage ... positive, statistically significant top-line results from its ANCHOR trial for ... met its primary and secondary efficacy endpoints for both the ... The purpose of the ANCHOR trial was to demonstrate that ...
... and SYDNEY, April 15, 2011 HeartWare International, ... a leading innovator of less invasive, miniaturized circulatory ... advanced heart failure, today announced the presentation of ... transplantation (BTT) study, ADVANCE, showing 180-day survival, using ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5
West 2 periosteal elevators....
Semb periosteal elevators....
Williger periosteal elevators....
Lambotte periosteal elevators....
Medicine Products: